Jump to content


  • Posts

  • Joined

  • Last visited

panguna's Achievements


Newbie (1/14)



  1. Clinuvel still commands a lot of support from the shorters. https://www.fool.com.au/2020/04/27/these-ar...-27-april-2020/
  2. Not only would humans benefit but some livestock as well.I remember the early days of Epitan, when farmers and veterinarians would talk about the need to give protection to certain animals, particularly ne Light-colored animals, newly shorn sheep and other animals that are clipped can suffer from sunburn and the parts of animals that normally lack hair cover can be sunburned. The problem can be worsened because animals may be exposed to certain substances from their feed, medications such as antibiotics, and spores of certain moulds, that can photo-sensitize them, making them more likely to burn; extreme sunburn and sometimes large open skin wounds can result.wly shorn sheep."
  3. My sincerest condolences....we will miss his wise and humorous analytical forecasts. R.I.P.
  4. X-Ray.....I trust you did this after consultations with your "Budgie". We don't hear much from him these days, is he still around..? Cheers and best of luck.
  5. That was some move......$4.50 on a volume @ 232202. Cheers.
  6. Not really sure on that one, I have an online trading a/c with my bank....NAB. It is fairly comprehensive with "live time" data, depth,volume, charts etc. Make some enquiries with your bank. Best of luck. Current price.....$5.10
  7. Definite "squeeze" on for shares.......$5.20.. up 45 cents [9.47%] ...volume 40829
  8. Currently trading @ $5.00......volume 38396.....buyers @ $5.....sellers @ $5.05 Cheers.
  9. For those who are interested, but missed reading the investor note at conclusion of J.V. announcement, this is worthwhile viewing: Investor note: please see for a 2009 video of Mr Jack Wood referencing the development vision of SCENESSE® into complementary products. The $500 million to $1 billion comment was of interest and that was made "way back then". Cheers
  10. Yes, I believe you are right. My understanding was, that the Company wanted to reduce the amount of "day traders" that were affecting the share price stability.
  11. There is a definate "squeeze" on for shares.Opened at $3.22, with buyers @ $3.30 and sellers @ $3.37.Only 12,820 on offer.Little surprised Clinuvel has not been hit with a please explain.Currently trading @ $3.30 Cheers.
  12. KRD......I think you will find that figure to be as per below $11,752.000 ** Payment for acquisition of, and proceeds from equity investments represents cash flows into financial instruments. These instruments do not meet the strict definition of a cash equivalent within AASB107 Cash Flow Statements, and are defined by the Standard to be financial assets held for trading, hence do not form part of Cash at end of quarter. As at 31st December 2011, the Cash at Bank and Investments in financial instruments total $11,752k
  13. A follow-up article to announcement: Clinuvel records $1m in SCENESSE sales 09:55, Thursday, 23 June 2011 Sydney - Thursday - June 23: (RWE Australian Business News) - Clinuvel Pharmaceuticals Ltd (ASX:CUV) has made a successful start to distribution of its new drug SCENESSE (afamelanotide) to the erythropoietic protoporphyria (EPP) patient community in Italy. Since commencing a special access 648/96 scheme 11 months ago, SCENESSE has been distributed to around 40 patients in Italy to treat EPP, a severe genetic disorder designated as an 'orphan' disease. Throughout the treatment period all patients have been followed up by EPP specialists and, significantly, no serious drug-related adverse events have been recorded. During this period the company recorded $1m worth of sales. It is reimbursed for the drug by the Italian health system. ***** Clinuvel will continue to distribute SCENESSE under the 648/96 scheme with the intention of expanding use of the photoprotective drug among EPP patients. EPP is characterised by severe phototoxicity of the skin resulting in intolerable pain, swelling, and scarring, usually of the exposed areas such as the face, hands and feet. EPP patients are often forced to lead an indoor existence, severely affecting their quality of life. Some 10,000 people are globally known to be affected by EPP, an estimated 4,000 across Europe. ENDS
  14. Follow-up article to announcement: -------------------------------------------- Phylogica in partnership with University of Cambridge 10:07, Wednesday, 9 March 2011 Sydney - Wednesday - March 9: (RWE Australian Business News) - Phylogica Ltd (ASX:PYC) will partner with researchers from the University of Cambridge to pursue a novel application of its Phylomer peptides for discovery of disease-associated targets. The new partnership complements Phylogica's existing business model by opening up a new market opportunity for the company. It offers the potential to secure new revenue streams that would otherwise not be accessible to Phylogica without substantial investment in both capital and also in technical expertise. Phylogica has initiated discussions with prospective partners who are interested in the capabilities of the new Phylogica-Cambridge University venture. ***** The new venture, named Phenomica, will combine Phylogica's Phylomer libraries, which comprise billions of naturally derived peptides, with technology from Cambridge to identify vulnerable points in a disease that can be the focus for new drug development. Phylogica has signed a memorandum of understanding with Cambridge Enterprise, the university's commercialisation group, outlining plans to form Phenomica. The business will be based in Cambridge, UK, maximising access to state-of-the-art research facilities. ENDS .
  15. The good news keeps rolling in,still does not help the s.p......! --------------------------------------------------------------------- Phylogica finds new potential for treating brain injury 12:23, Monday, 21 February 2011 Sydney - Monday - February 21: (RWE Aust Business News) -Phylogica (ASX:PYC), has successfully demonstrated pre-clinical proof of concept with a Phylomer peptide drug candidate for the treatment of traumatic brain injury. Using an internationally established pre-clinical model, a three-year collaborative study with the Australian Neuromuscular Research Institute and the University of Tasmania has shown the compound, known as PYCAG5, is able to protect neural tissue at lesion sites and significantly reduce inflammation. The peptide was identified using Phylogica's proprietary Phylomer drug discovery platform and the study was funded by the Neurotrauma Research Program (NRP) of the Western Australia Institute of Medical Research. Chief executive Paul Watt said he was particularly encouraged by these results, which could eventually pave the way for better outcomes in head injury patients around the world. "While several Phylomer peptides showed neuroprotective activity in this brain trauma model this particular peptide, PYCAG5, showed outcomes most consistent with therapeutic potential," he said. "This Phylomer significantly protected neural issue in the vicinity of the lesion at four days after the induced head injury and decreased the extent of inflammation, increasing the potential for healing at seven days post injury." Dr Watt indicated the average loss of neurons from the injured region treated with Phylomer PYCAG5 was less than a third of the average loss observed for mock-treated control animals, or animals treated with a non-Phylomer peptide. Phylogica is now pursuing partnering opportunities with major pharmaceutical and biotech companies for further development of its lead candidate, PYCAG5, and the company's other neuroprotective Phylomers. ENDS Copyright © 2011 RWE Australian Business News. All rights reserved.
  • Create New...